Open call for additional technology partners (D6.5)
Lead Contributors: Nathalie Vigot (UMCU PMO)
June 21, 2021
The Trials@Home pan-European pilot (pan-EU pilot) study aims at comparing traditional clinical trial approaches to fully and hybrid RDCT approaches; as well as comparatively analyse the components (traditional clinical trial and hybrid and/or fully RDCT) in the pan-EU pilot and present and refine key performance indicators (KPIs) to qualify and quantify the flow of activities, subject perception, cost, quality and compliance.
Several technology/service providers were added to the Trials@Home project in order to ensure access to state-of-the-art technologies for the pilot Remote Decentralised Clinical Trial (RDCT) and to fulfil the relevant tasks identified in the Technology Package of WP2 TECH. This technology package and the proposed additional technology/service participants were selected through an external Request for Proposals (RfP ).
The Trials@Home RfP has been developed in consultation with IMI to ensure compliance with the relevant EU and EU H2020 procedures and regulations. It described in detail the application requirements and procedures, timelines and templates to be used, as well as the eligibility and evaluation criteria and processes applied. A list of quality criteria was developed for the open call and published in “D2.2 Detailed list of Quality assessment criteria and assessment procedures”.
This public report describes the process of selecting additional technology/service providers for providing technologies to be deployed in the Trials@Home pan-EU pilot study.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831458. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Notes for editors – not for publication
If you would like more information, please contact the spokesperson at the UMC Utrecht.
Joris Prinssen: +31 6 2571 0234